How I treat refractory acute GVHD.
暂无分享,去创建一个
[1] M. Sorror,et al. Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens , 2008, Bone Marrow Transplantation.
[2] H. Deeg,et al. Acute Graft-versus-Host Disease , 2008 .
[3] K. Sullivan. Graft‐vs.‐Host Disease , 2007 .
[4] D. Jacobsohn,et al. Acute graft-versus-host disease. , 1990, Cancer treatment and research.
[5] M. Horowitz,et al. Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. , 2007, Tissue antigens.
[6] H. Deeg,et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. , 2007, Blood.
[7] M. Sayegh,et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. , 2006, Journal of the American Society of Nephrology : JASN.
[8] T. Banović,et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. , 2006, Blood.
[9] J. Ritz,et al. Rituximab for steroid-refractory chronic graft-versus-host disease. , 2006, Blood.
[10] A. Bacigalupo,et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. , 2006, Blood.
[11] P. Bruzzi,et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] E. Shpall,et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. , 2006, Blood.
[13] F. Foss. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation. , 2006, Seminars in hematology.
[14] D. Hockenbery,et al. Oral beclomethasone dipropionate (BDP) for gastrointestinal GVHD: A corticosteroid-sparing treatment with improved survival at day +200 , 2006 .
[15] D. Couriel,et al. Graft-versus-host disease after allogeneic stem cell transplantation: evolving concepts and novel therapies including photopheresis. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] C. Anasetti. The 2006 BBMT Education Supplement. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[17] D. Peritt. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] M. Maris,et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. , 2005, Blood.
[19] J. Serody,et al. Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. , 2005, Blood.
[20] B. Storer,et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[21] F. Foss,et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors , 2005, Bone Marrow Transplantation.
[22] M. Turner,et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[23] J. Radich,et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2004, Blood.
[24] Allen R. Chen,et al. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[25] D. Zahrieh,et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. , 2004, Blood.
[26] J. Ritz,et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. , 2004, Blood.
[27] C. Craddock,et al. Successful use of Campath-1H in the treatment of steroid refractory liver GvHD , 2004, Bone Marrow Transplantation.
[28] M. Remberger,et al. Dose Study of Thymoglobulin During Conditioning for Unrelated Donor Allogeneic Stem-Cell Transplantation , 2004, Transplantation.
[29] Moustapha Hassan,et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.
[30] K. Cleary,et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[31] V. Vitale,et al. High dose bolus methylprednisolone for the treatment of acute graft versus host disease , 1983, Blut.
[32] F. Appelbaum,et al. Thomas' hematopoietic cell transplantation , 2003 .
[33] M. Maris,et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.
[34] J. Sanders,et al. Steroid‐refractory graft‐vs.‐host disease: past, present and future , 2003, Pediatric transplantation.
[35] C. Craddock,et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. , 2002, Blood.
[36] Paul Martin,et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. , 2002, Blood.
[37] R. Storb,et al. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[38] J. Wagner,et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[39] T. Schumacher,et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens , 2002, Nature Medicine.
[40] H. Deeg,et al. SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE1 , 2001, Transplantation.
[41] H. Deeg,et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. , 2001, Blood.
[42] S. Lord,et al. The impaired polymerization of fibrinogen Longmont (Bbeta166Arg-->Cys) is not improved by removal of disulfide-linked dimers from a mixture of dimers and cysteine-linked monomers. , 2001, Blood.
[43] D. Couriel,et al. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation , 2000, Current opinion in oncology.
[44] H. Deeg,et al. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities , 2000, Bone Marrow Transplantation.
[45] F. Puglisi,et al. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy. , 2000, Seminars in oncology.
[46] H. Greinix,et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. , 2000, Blood.
[47] B. Blazar,et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[48] G. Vogelsang,et al. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease. , 2000, Seminars in oncology.
[49] K. Oshimi,et al. A Metalloproteinase Inhibitor Prevents Acute Graft-Versus-Host Disease While Preserving the Graft-Versus-Leukaemia Effect of Allogeneic Bone Marrow Transplantation , 2000, Leukemia & lymphoma.
[50] K. Atkinson. Clinical bone marrow and blood stem cell transplantation , 2000 .
[51] W. Kreisel,et al. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD , 1999, Bone Marrow Transplantation.
[52] E. Jaffe,et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. , 1999, Blood.
[53] M. Shlomchik,et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. , 1999, Science.
[54] L. Sehn,et al. A Phase II Study of BTI-322, a Monoclonal Anti-CD2 Antibody, for Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease , 1998 .
[55] G. Dini,et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. , 1998, Blood.
[56] D. Levine,et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. , 1998, Gastroenterology.
[57] H. V. van Houwelingen,et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. , 1996, The New England journal of medicine.
[58] H. Deeg,et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. , 1996, Blood.
[59] R. Krance,et al. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1 , 1995, The Lancet.
[60] H. Einsele,et al. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. , 1995, Bone marrow transplantation.
[61] P. Tiberghien,et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. , 1992, Blood.
[62] L. Pickle,et al. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. , 1991, Bone marrow transplantation.
[63] A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment , 1990 .
[64] D. Weisdorf,et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. , 1990, Blood.
[65] K. Sullivan,et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. , 1990, Blood.
[66] R. Storb,et al. A randomized trial of antihuman thymocyte globulin versus murine monoclonal antihuman T-cell antibodies as immunosuppressive therapy for aplastic anemia. , 1985, Experimental hematology.
[67] P. Neiman,et al. CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.
[68] R. Billingham. The biology of graft-versus-host reactions. , 1966, Harvey lectures.
[69] E. Shelton,et al. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. , 1951, Journal of the National Cancer Institute.
[70] Frimm Ce. New progress in the treatment of macrocytic anemia , 1951 .